Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2021 / N 1

Ингаляционная медикаментозная терапия при бронхоэктазии
Э.Х. Анаев

References

1. Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn JS, Floto RA, Grillo L, Gruffydd-Jones K, Harvey A, Haworth CS, Hiscocks E, Hurst JR, Johnson C, Kelleher PW, Bedi P, Payne K, Saleh H, Screaton NJ, Smith M, Tunney M, Whitters D, Wilson R, Loebinger MR. British Thoracic Society guideline for bronchiectasis in adults. Thorax 2019 Jan;74(Suppl 1):1-69.
2. Martínez-García MA, Máiz L, Olveira C, Girón RM, de la Rosa D, Blanco M, Cantón R, Vendrell M, Polverino E, de Gracia J, Prados C. Spanish guidelines on treatment of bronchiectasis in adults. Archivos de Bronconeumología (English Edition) 2018 Feb;54(2):88-98.
3. Ferri S, Crimi C, Heffler E, Campisi R, Noto A, Crimi N. Vitamin D and disease severity in bronchiectasis. Respiratory Medicine 2019 Mar;148:1-5.
4. Guan WJ, Han XR, de la Rosa-Carrillo D, Martinez-Garcia MA. The significant global economic burden of bronchiectasis: a pending matter. The European Respiratory Journal 2019 Feb;53(2):1802392.
5. Cole PJ. Inflammation: a two-edged sword – the model of bronchiectasis. European Journal of Respiratory Diseases. Supplement 1986;147:6-15.
6. Quint JK, Millett ER, Joshi M, Navaratnam V, Thomas SL, Hurst JR, Smeeth L, Brown JS. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. The European Respiratory Journal 2016 Jan;47(1):186-93.
7. Ringshausen FC, de Roux A, Diel R, Hohmann D, Welte T, Rademacher J. Bronchiectasis in Germany: a population-based estimation of disease prevalence. The European Respiratory Journal 2015 Dec;46(6):1805-7.
8. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris-Espin M, Cantón R, Torres A, Dimakou K, De Soyza A, Hill AT, Haworth CS, Vendrell M, Ringshausen FC, Subotic D, Wilson R, Vilaró J, Stallberg B, Welte T, Rohde G, Blasi F, Elborn S, Almagro M, Timothy A, Ruddy T, Tonia T, Rigau D, Chalmers JD. European Respiratory Society guidelines for the management of adult bronchiectasis. The European Respiratory Journal 2017 Sep;50(3):1700629.
9. Antoniu SA. Investigational inhaled therapies for non-CF bronchiectasis. Expert Opinion in Investigational Drugs 2018 Jan;27(2):1-8.
10. Hewitt WL. Antibiotic therapy of abscess of the lung and bronchiectasis. California Medicine 1952 May;76(5):319-24.
11. Chen CI, Huang Y, Gao YH, Chena RC, Zhonga NS, Guan WJ. Inhaled medication therapy for bronchiectasis: status quo and the next frontier. Expert Opinion on Investigational Drugs 2018;27(3):211-8.
12. O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998 May;113(5):1329-34.
13. Karadag B, Karakoc F, Ersu R, Kut A, Bakac S, Dagli E. Non-cystic-fibrosis bronchiectasis in children: a persisting problem in developing countries. Respiration 2005 May-Jun;72(3):233-8.
14. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2012 Oct;186(7):657-65.
15. Hnin K, Nguyen C, Carson KV, Evans DJ, Greenstone M, Smith BJ. Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults. The Cochrane Database of Systematic Reviews 2015 Aug;2015(8):CD001392.
16. Çağdaş D, Pehlivantürk Kizılkan M, Tagiyev A, Emiralioğlu N, Keleş A, Yalçın E, Doğru D, Özçelik U, Kiper N, Tezcan İ. Primary immunodeficiency disorders in children with non-cystic fibrosis bronchiectasis. European Annals of Allergy and Clinical Immunology 2020 Nov;52(6):271-6.
17. Dimakou K, Triantafillidou C, Toumbis M, Tsikritsaki K, Malagari K, Bakakos P. Non CF-bronchiectasis: aetiologic approach, clinical, radiological, microbiological and functional profile in 277 patients. Respiratory Medicine 2016 Jul;116:1-7.
18. Janas A, Przybylski P. 14- and 15-membered lactone macrolides and their analogues and hybrids: structure, molecular mechanism of action and biological activity. European Journal of Medicinal Chemistry 2019 Nov;182:111662.
19. European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2019. Surveillance report 18 Nov 2020.
20. Inchingolo R, Pierandrei C, Montemurro G, Smargiassi A, Lohmeyer FM, Rizzi A. Antimicrobial resistance in common respiratory pathogens of chronic bronchiectasis patients: a literature review. Antibiotics (Basel, Switzerland) 2021 Mar;10(3):326.
21. Smith S, Rowbotham NJ, Charbek E. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. The Cochrane Database of Systematic Reviews 2018 Oct;10(10):CD008319.
22. Laska IF, Crichton ML, Shoemark A, Chalmers JD. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. The Lancet. Respiratory Medicine 2019 Oct;7(10):855-69.
23. Sangiovanni S, Morales EI, Fernández-Trujillo L. Inhaled tobramycin for chronic infection with Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. Respiratory Medicine 2021 Jan;176:106283.
24. Ho C, Severn M. Colistin for prophylactic use in non-cystic fibrosis bronchiectasis or COPD with exacerbations: a review of clinical and cost-effectiveness and guidelines. Canadian Agency for Drugs and Technologies in Health (CADTH) rapid response reports. Ottawa, ON: 2017. Available from: http://www.ncbi.nlm.nih.gov/books/NBK493389/ Accessed 2021 Jul 14.
25. De Soyza A, Aksamit T, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. The European Respiratory Journal 2018 Jan;51(1):1702052.
26. Aksamit T, De Soyza A, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. The European Respiratory Journal 2018 Jan;51(1):1702053.
27. Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O’Donnell AE. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. The Lancet. Respiratory Medicine 2019 Mar;7(3):213-26.
28. Murray MP, Govan JR, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, Greening AP, Haslett C, Hill AT. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2011 Feb;183(4):491-9.
29. Barker AF, O’Donnell AE, Flume P, Thompson PJ, Ruzi, JD, De Gracia J, Boersma WG, De Soyza A, Shao L, Zhang J, Haas L, Lewis SA, Leitzinger S, Montgomery AB, McKevitt MT, Gossage D, Quittner AL, O’Riordan TG. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. The Lancet. Respiratory Medicine 2014 Sep;2(9):738-49.
30. Orriols R, Hernando R, Ferrer A, Terradas S, Montoro B. Eradication therapy against Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. Respiration 2015;90(4):299-305.
31. Drobnic ME, Suñé P, Montoro JB, Ferrer A, Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. The Annals of Pharmacotherapy 2005 Jan;39(1):39-44.
32. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. American Journal of Respiratory and Critical Care Medicine 2014 Apr;189(8):975-82.
33. Kocurek EG, Jagana R. Noncystic fibrosis bronchiectasis management: opportunities and challenges. Current Opinion in Pulmonary Medicine 2019 Mar;25(2):192-200.
34. Spencer S, Felix LM, Milan SJ, Normansell R, Goeminne PC, Chalmers JD, Donovan T. Oral versus inhaled antibiotics for bronchiectasis. The Cochrane Database of Systematic Reviews 2018 Mar;3(3):CD012579.
35. White L, Mirrani G, Grover M, Rollason J, Malin A, Suntharalingam J. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respiratory Medicine 2012 Mar;106(3):356-60.
36. Dhand R. The rationale and evidence for use of inhaled antibiotics to control Pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery 2018 Jun;31(3):121-38.
37. Ohta S. Molecular hydrogen as a novel antioxidant: overview of the advantages of hydrogen for medical applications. Methods in Enzymology 2015;555:289-317.
38. Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Li HM, Li ZM, Zheng JP, Chen RC, Zhong NS. Effect of airway Pseudomonas aeruginosa isolation and infection on steady-state bronchiectasis in Guangzhou, China. Journal of Thoracic Disease 2015 Apr;7(4):625-36.
39. Goyal V, Chang AB. Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis. The Cochrane Database of Systematic Reviews 2014 Jun;2014(6):CD010327.
40. Tarrant BJ, Le Maitre C, Romero L, Steward R, Button BM, Thompson BR, Holland AE. Mucoactive agents for chronic, non-cystic fibrosis lung disease: a systematic review and meta-analysis. Respirology 2017 Aug;22(6):1084-92.
41. Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS Supplement 2013 May;136:1-51.
42. Lebeaux D, Ghigo JM, Beloin C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiology and Molecular Biology Reviews 2014 Sep;78(3):510-43.
43. Davies D. Understanding biofilm resistance to antibacterial agents. Nature Reviews. Drug Discovery 2003 Feb;2(2):114-22.
44. Barratt SL, Creamer A, Hayton C, Chaudhuri N. Idiopathic pulmonary fibrosis (IPF): an overview. Journal of Clinical Medicine 2018 Aug;7(8):201.
45. Calverley P, Rogliani P, Papi A. Safety of N-acetylcysteine at high doses in chronic respiratory diseases: a review. Drug Safety 2021 Mar;44(3):273-90.
46. Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Molecular Immunology 2013 Aug;55(1):27-34.
47. Marsh RL, Thornton RB, Smith-Vaughan HC, Richmond P, Pizzutto SJ, Chang AB. Detection of biofilm in bronchoalveolar lavage from children with non-cystic fibrosis bronchiectasis. Pediatric Pulmonology 2015 Mar;50(3):284-92.
48. Tunney MM, Einarsson GG, Wei L, Drain M, Klem ER, Cardwell C, Ennis M, Boucher RC, Wolfgang MC, Elborn JS. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. American Journal of Respiratory and Critical Care Medicine 2013 May;187(10):1118-26.
49. Hall-Stoodley L, Hu FZ, Gieseke A, Nistico L, Nguyen D, Hayes J, Forbes M, Greenberg DP, Dice B, Burrows A, Wackym PA, Stoodley P, Post JC, Ehrlich GD, Kerschner JE. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 2006 Jul;296(2):202-11.
50. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. The Lancet 2001 Jul;358(9276):135-8.
51. Bryers JD, Jarvis RA, Lebo J, Prudencio A, Kyriakides TR, Uhrich K. Biodegradation of poly(anhydride-esters) into non-steroidal anti-inflammatory drugs and their effect on Pseudomonas aeruginosa biofilms in vitro and on the foreign-body response in vivo. Biomaterials 2006 Oct;27(29):5039-48.
52. Pérez-Giraldo C, Rodríguez-Benito A, Morán FJ, Hurtado C, Blanco MT, Gómez-García AC. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. The Journal of Antimicrobial Chemotherapy 1997 May;39(5):643-6.
53. Zhao T, Liu Y. N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa. BMC Microbiology 2010 May;12(10):140.
54. Kashef N, Karami S, Djavid GE. Phototoxic effect of hypericin alone and in combination with acetylcysteine on Staphylococcus aureus biofilms. Photodiagnosis and Photodynamic Therapy 2015 Jun;12(2):186-92.
55. Lea J, Conlin AE, Sekirov I, Restelli V, Ayakar KG, Turnbull L, Doyle P, Noble M, Rennie R, Schreiber WE, Westerberg BD. In vitro efficacy of N-acetylcysteine on bacteria associated with chronic suppurative otitis media. Journal of Otolaryngology – Head & Neck Surgery 2014 Jul;43(1):20.
56. del Prado G, Ruiz V, Naves P, Rodríguez-Cerrato V, Soriano F, del Carmen Ponte M. Biofilm formation by Streptococcus pneumoniae strains and effects of human serum albumin, ibuprofen, N-acetyl-l-cysteine, amoxicillin, erythromycin, and levofloxacin. Diagnostic Microbiology and Infectious Diseases 2010 Aug;67(4):311-8.
57. Riise GC, Qvarfordt I, Larsson S, Eliasson V, Andersson BA. Inhibitory effect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilus influenzae to human oropharyngeal epithelial cells in vitro. Respiration 2000;67(5):552-8.
58. Zheng CH, Ahmed K, Rikitomi N, Martinez G, Nagatake T. The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiology and Immunology 1999;43(2):107-13.
59. Olofsson AC, Hermansson M, Elwing H. N-acetyl-L-cysteine affects growth, extracellular polysaccharide production, and bacterial biofilm formation on solid surfaces. Applied and Environmental Microbiology 2003 Aug;69(8):4814-22.
60. Blasi F, Page C, Rossolini GM, Pallecchi L, Matera MG, Rogliani P, Cazzola M. The effect of N-acetylcysteine on biofilms: implications for the treatment of respiratory tract infections. Respiratory Medicine 2016 Aug;117:190-7.
61. Marchese A, Debbia EA, Tonoli E, Gualco L, Schito AM. In vitro activity of thiamphenicol against multiresistant Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in Italy. Journal of Chemotherapy 2002 Dec;14(6):554-61.
62. Ivanchik NV, Sukhorukova MV, Chagaryan AN, Trushin IV, Dekhnich AV, Kozlov RS. In vitro activity of thiamphenicol against Haemophilus influenzae, Streptococcus pneumoniae and Streptococcus pyogenes clinical isolates. Clinical Microbiology and Antimicrobial Chemotherapy 2021;23(1):92-9 (In Russian).
63. Kapustina V, Ovcharenko S. The efficacy and safety of inhaled fluimucil-antibiotic-IT in the treatment of exacerbations of COPD and chronic bronchitis with bronchiectasis. The European Respiratory Journal 2013;42:P1535.
64. Serra A, Schito GC, Nicoletti G, Fadda G. A therapeutic approach in the treatment of infections of the upper airways: thiamphenicol glycinate acetylcysteinate in sequential treatment (systemic-inhalatory route). International Journal of Immunopathology and Pharmacology 2007 Jul-Sep;20(3):607-17.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]